For example, while cases with both IGHV-unmutated status and TP53 mutations were associated with more aggressive disease (13), one CLL patient with co-occurring chromothripsis and chromoplexy but wild-type TP53 remained clinically stable for over two years (9). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.